Back to search results

Elecoglipron vs. Semaglutide for Type 2 Diabetes

This study is looking for adults with Type 2 Diabetes Mellitus (T2DM) whose blood sugar isn't well-controlled with their current treatment or lifestyle changes. You might be able to join if you've had T2DM for at least 90 days and your HbA1c (a measure of average blood sugar over 2-3 months) is between 7% and 10.5%. The study will compare a new oral medication called Elecoglipron to an existing oral medication, Semaglutide, to see how well they lower blood sugar and if they are safe. Researchers will measure your HbA1c from the start of the study up to 52 weeks to see if the medications are working. The study aims to enroll about 1200 participants, but its current recruitment status is unclear.

Study design
This is an interventional study comparing two different oral medications, Elecoglipron and Semaglutide, in about 1200 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your HbA1c will be measured from the start of the study up to 52 weeks to track your progress.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07662213

A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus

Recruiting
PHASE3Ages 18+InterventionalTreatment
AstraZeneca
~1,200 participants
Updated 2026-07-14 on ClinicalTrials.gov
What's tested:ElecoglipronSemaglutide

At a glance

Recruiting sites
9 of 201 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change from baseline in Hemoglobin A1c (HbA1c)
Measured over Baseline to Week 52

Conditions

Type 2 Diabetes Mellitus

Explore related trials

Type 2 Diabetes Mellitus

Where it's being run

201 sites across 46 states
Germany19
China15
Japan14
United Kingdom12
Taiwan10
Texas9
Italy9
Australia8

Who to contact

AstraZeneca Clinical Study Information Center
[email protected]
1-877-240-9479
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Diagnosed with Type 2 Diabetes Mellitus (T2DM) for at least 90 days prior to screening
T2DM inadequately managed with lifestyle management alone or on stable treatment with other background glucose-lowering medication(s)
HbA1c value of ≥ 7% to ≤ 10.5% (53 to 91.3 mmol/mol)
Increased risk of cardiovascular (CV) events defined by ≥1 of: documented coronary heart disease, peripheral arterial disease, ischemic cerebrovascular disease, or heart failure (NYHA II-III); or ≥2 CV risk factors
Body mass index (BMI) of ≥ 23 kg/m2 at screening
Stable body weight (self-reported or documented) for 90 days prior to screening

Exclusion

Type 1 Diabetes Mellitus (T1DM), secondary forms of diabetes (including congenital forms), or history of ketoacidosis or hyperosmolar coma
Currently receiving or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema
Have had more than one episode of severe hypoglycemia within 180 days prior to screening or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms
Clinically significant condition affecting the upper Gastrointestinal (GI) tract or chronic use of any medication that affects gastric motility or gastric emptying
History of acute or chronic pancreatitis
Severe congestive heart failure (NYHA IV)
History/family history of medullary thyroid cancer or multiple endocrine neoplasia type 2

What this trial measures

  • Change from baseline in Hemoglobin A1c (HbA1c)Baseline to Week 52